To determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction.
Age 18 years or older.
Presence of stable angina symptoms, defined as compatible symptoms occurring at least once weekly in the last three months.
Absence of functionally significant epicardial coronary artery disease (FFR > 0.80).
Microvascular functional study showing CFR< 2,0 and/or IMR ≥ 25.
Allergy or contraindication to the use of beta-blockers.
Indication for beta-blocker treatment due to another pathology.
Ventricular dysfunction (LVEF < 45%).
Percutaneous coronary revascularization in the last 6 months.